Due to the significant association of the SLC7A5+SLC3A2+ subgroup of patients with a high rate of mitotic activity (p < 0.0001), we next investigated if SLC7A5/SLC3A2 co-expression is associated with proliferation of ER+ breast cancer. The gene discussed is SLC3A2; the disease is breast cancer.